Zenith Technologies and GE Healthcare Life Sciences to Collaborate on Biopharmaceutical Manufacturing Deployment
As part of the partnership, Zenith Technologies’ methodologies, systems, and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing.
Zenith Technologies and GE Healthcare’s Life Sciences business will collaborate on biopharmaceutical manufacturing deployment, according to an April 4, 2016 press announcement.
According to the press announcement, as part of the partnership, Zenith Technologies’ methodologies, systems, and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing. The two companies will integrate process control systems, manufacturing execution system (MES) solutions, and other supporting technologies with GE Healthcare’s technologies and solutions for the biopharmaceutical manufacturing industry.
"The development of our KUBio modular manufacturing facilities and FlexFactory single-use manufacturing platform was fuelled by the need for customers to deploy biopharmaceutical manufacturing capacity more quickly and at a lower cost,” said Jan Makela, general manager at BioProcess GE Healthcare in a statement. “Implementing these advanced technology platforms requires automation expertise for which we partner with a number of world class companies.”
Source: Zenith Technologies
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
